International Journal of Hematology and Oncology 2022, Vol 32, Num 3 Page(s): 185-194

Gülsüm E. PAMUK1, Ferda HARMANDAR2, Orbay HARMANDAR2, Burhan TURGUT1, Emre TEKGÜNDÜZ1, Muzaffer DEMİR1, Özden VURAL1

1Trakya Üniversitesi Tıp Fakültesi Hematoloji Bilim Dalı, EDİRNE
2Trakya Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, EDİRNE

Keywords: Non-Hodgkin lymphoma, Prognosis, CHOP, Rituximab
The clinical features, histopathological types, treatment modalities and response, and survival analysis were evaluated in our 114 patients with non-Hodgkin lymphoma (NHL). At initial diagnosis, 10% had stage I, 14% stage II, 30% stage III, and 46% stage IV disease according to Cotswold classification. Therapy was administered to 101 (89%) NHL subjects at initial diagnosis. CHOP was given to 57 (56%) and rituximab (R)-CHOP to 17 (17%) cases. The highest rate of complete remission was in R-CHOP group (83%). The median survival of NHL subjects was 52 months. 3-year survival was 54%, 5-year survival was 46%. Survival of very aggressive lymphoma patients (3 months) was shorter than that of aggressive (41 months) and indolent (86 months) patients (p values<0.05). The median survival of stage IV subjects at initial diagnosis (26 months) was shorter than stage I (not reached), stage II (86 months) and stage III (96 months) cases (p values <0.05). Survival of patients with B symptoms, extranodal and bone marrow involvement, unresponsive to first-line therapy, IPI> 2 at initial diagnosis was shorter than others (p values <0.05). Cox regression analysis showed that unresponsiveness to first-line therapy (OR:11.6, p=0.001) was an independent poor prognostic factor. It was interesting that combined chemotherapy with rituximab achieved a high rate of complete remission when given as first-line therapy.